Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DSGN NASDAQ:TDUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDSGNDesign Therapeutics$14.10-3.1%$11.62$3.11▼$17.25$908.75M1.73540,056 shs394,077 shsTDUPThredUp$4.92-2.4%$3.93$3.08▼$12.28$640.27M2.072.64 million shs2.89 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDSGNDesign Therapeutics-3.09%+3.68%+15.38%+37.29%+327.01%TDUPThredUp-2.38%+14.69%+40.57%0.00%-23.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDSGNDesign Therapeutics$14.10-3.1%$11.62$3.11▼$17.25$908.75M1.73540,056 shs394,077 shsTDUPThredUp$4.92-2.4%$3.93$3.08▼$12.28$640.27M2.072.64 million shs2.89 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDSGNDesign Therapeutics-3.09%+3.68%+15.38%+37.29%+327.01%TDUPThredUp-2.38%+14.69%+40.57%0.00%-23.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDSGNDesign Therapeutics 2.86Moderate Buy$16.5017.02% UpsideTDUPThredUp 2.86Moderate Buy$9.1485.77% UpsideCurrent Analyst Ratings BreakdownLatest DSGN and TDUP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026TDUPThredUp TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $5.705/5/2026TDUPThredUp Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$10.00 ➝ $8.005/5/2026TDUPThredUp Telsey Advisory GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $7.005/4/2026DSGNDesign Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $21.004/29/2026DSGNDesign Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$20.004/29/2026TDUPThredUp TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $5.504/20/2026DSGNDesign Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026TDUPThredUp TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/6/2026TDUPThredUp TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.003/27/2026TDUPThredUp Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/16/2026DSGNDesign Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDSGNDesign TherapeuticsN/AN/AN/AN/A$3.49 per shareN/ATDUPThredUp$310.81M2.01N/AN/A$0.47 per share10.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDSGNDesign Therapeutics-$69.79M-$1.20N/AN/AN/AN/A-33.07%-31.29%N/ATDUPThredUp-$20.21M-$0.16N/AN/AN/A-6.68%-36.11%-12.53%N/ALatest DSGN and TDUP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/4/2026Q1 2026TDUPThredUp-$0.05-$0.05N/A-$0.05$80.17 million$81.67 million4/28/2026Q1 2026DSGNDesign Therapeutics-$0.36-$0.29+$0.07-$0.29N/AN/A3/9/2026Q4 2025DSGNDesign Therapeutics-$0.38-$0.27+$0.11-$0.27N/AN/A3/2/2026Q4 2025TDUPThredUp-$0.04-$0.04N/A-$0.04$77.17 million$79.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDSGNDesign TherapeuticsN/AN/AN/AN/AN/ATDUPThredUpN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDSGNDesign TherapeuticsN/A22.2822.28TDUPThredUp0.300.950.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDSGNDesign Therapeutics56.64%TDUPThredUp89.08%Insider OwnershipCompanyInsider OwnershipDSGNDesign Therapeutics23.50%TDUPThredUp23.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDSGNDesign Therapeutics4062.46 million47.78 millionOptionableTDUPThredUp2,132127.04 million97.69 millionOptionableDSGN and TDUP HeadlinesRecent News About These CompaniesEquities Analysts Offer Predictions for ThredUp Q3 Earnings3 minutes ago | marketbeat.comAnalysts Are Bullish on These Consumer Cyclical Stocks: thredUP (TDUP), Ferrari (RACE)May 7 at 12:57 PM | theglobeandmail.comAnalysts Are Bullish on These Consumer Cyclical Stocks: thredUP (TDUP), DoorDash (DASH)May 6 at 3:20 PM | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Consumer Cyclical Companies: thredUP (TDUP), Home Depot (HD) and Allison Transmission Holdings (ALSN)May 6 at 10:19 AM | theglobeandmail.comThredUp Doubles Down on Resale-as-a-Service® (RaaS®); Appoints Strategic Advisory Board to Scale Universal Recommerce LayerMay 6 at 9:15 AM | globenewswire.comThredUp Q1 Loss Meets Estimates, Adjusted EBITDA Margin ShrinksMay 5 at 12:41 PM | zacks.comThredUp (NASDAQ:TDUP) Shares Gap Up - Here's WhyMay 5 at 11:56 AM | marketbeat.comTDUP Q1 deep dive: Buyer growth and AI initiatives offset macro headwindsMay 5 at 8:42 AM | msn.comThredUp (NASDAQ:TDUP) Price Target Cut to $7.00 by Analysts at Telsey Advisory GroupMay 5 at 7:04 AM | marketbeat.comThredUp Inc. (TDUP) Q1 2026 Earnings Call TranscriptMay 4, 2026 | seekingalpha.comThredUp AI Agents Personalize Shopping in Real TimeMay 4, 2026 | pymnts.comThredUp Q1 Earnings Call HighlightsMay 4, 2026 | marketbeat.comThredUp (NASDAQ:TDUP) exceeds Q1 CY2026 expectationsMay 4, 2026 | msn.comThredUp (TDUP) Q1 2026 Earnings TranscriptMay 4, 2026 | finance.yahoo.comThredUp (NASDAQ:TDUP) Announces Quarterly Earnings Results, Meets EstimatesMay 4, 2026 | marketbeat.comThredUp Announces First Quarter 2026 ResultsMay 4, 2026 | globenewswire.comThredUp (TDUP) Reports Q1: Everything You Need To Know Ahead Of EarningsMay 3, 2026 | finance.yahoo.comWhy The ThredUp (TDUP) Investment Story Is Shifting As Analyst Targets ResetMay 3, 2026 | finance.yahoo.comTD Cowen Increases ThredUp (NASDAQ:TDUP) Price Target to $5.50April 29, 2026 | marketbeat.comThredUp (TDUP) to Release Quarterly Earnings on MondayApril 27, 2026 | marketbeat.com5 Most Shorted Penny Stocks to BuyApril 25, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDSGN and TDUP Company DescriptionsDesign Therapeutics NASDAQ:DSGN$14.10 -0.45 (-3.09%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$13.82 -0.28 (-2.01%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.ThredUp NASDAQ:TDUP$4.92 -0.12 (-2.38%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$4.92 0.00 (-0.10%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ThredUp Inc., together with its subsidiaries, operates an online resale platform in the United States and internationally. Its platform enables consumers to buy and sell primarily secondhand apparel, shoes, and accessories. ThredUp Inc. was incorporated in 2009 and is headquartered in Oakland, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
